Opendata, web and dolomites


System for AcceleroMeter-Based Assessment of cardiac FUNction

Total Cost €


EC-Contrib. €






 SAMBAfun project word cloud

Explore the words cloud of the SAMBAfun project. It provides you a very rough idea of what is the project "SAMBAfun" about.

complementary    monitoring    risk    turn    cardiaccs    patients    time    life    escape    reimbursement    alert    technologies    positions    whereas    detect    accessibility    surgical    ipr    trusted    opinion    cardisense    solution    german    regulatory    soon    contractility    sme    appear    offs    hospitals    health    mortality    profile    accurate    severe    hospitalization    extensive    myocardial    picked    morbidity    markets    leads    dominates    surgeons    complications    detection    functioning    undergoing    device    invasiveness    marker    cardiac    adding    trade    pace    biosignal    ties    input    perioperative    heart    credible    market    leader    events    brings    surgery    data    aarhus    chain    certification    standard    economic    patented    global    surgeries    smes    oslo    monitor    24h    osypka    quality    post    track    motion    nurses    sambafun    berlin    axis    lower    distributors    accuracy    accelerometer    days    routinely    continuous    models    function    latest    epicardial    analysed    complication   

Project "SAMBAfun" data sheet

The following table provides information about the project.


Organization address
address: Maridalsveien 71B
city: Oslo
postcode: 458
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 3˙688˙711 €
 EC max contribution 2˙918˙312 € (79%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDIACCS AS NO (Oslo) coordinator 1˙107˙221.00
2    OSYPKA AG DE (RHEINFELDEN BADEN) participant 690˙375.00
3    AARHUS UNIVERSITET DK (AARHUS C) participant 487˙312.00
4    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 454˙903.00
5    DEUTSCHES HERZZENTRUM BERLIN DE (BERLIN) participant 178˙500.00


 Project objective

In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients.

For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.

Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data.

SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.


List of deliverables.
Website Websites, patent fillings, videos etc. 2020-03-06 19:00:23

Take a look to the deliverables list in detail:  detailed list of SAMBAfun deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAMBAFUN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAMBAFUN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

BIOSNAP (2019)


Read More  

GIoT (2019)

Nano-satellites based Global Infrastructure to Enable IoT/M2M Networks - GIoT (Global IoT)

Read More